Prostasin

Quick links to important sections

Prostasin

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prostasin

Property Description
Active ingredient Terazosin hydrochloride
Form Oral tablets
Pharmacological class Alpha-1 Adrenergic Blocker
Origin Synthetic compound
Type Prescription-only medicine

What Type of Medicine is Prostasin (Terazosin)?

Prostasin is an oral pharmaceutical preparation containing the active ingredient, Terazosin hydrochloride, which is exclusively classified as a prescription-only medicine. Chemically, Terazosin is a synthetic compound derived from the Quinazoline structural family and is typically supplied for oral administration in tablet form. This formulation is clinically recognized for its high specificity within its class, distinguishing it from older, less-selective agents.

The drug's fundamental identity lies in its pharmacological class: it is an Alpha-1 Adrenergic Blocker, also known as an Alpha-1 Antagonist. This class of drug acts on receptors that control involuntary muscle tone and constriction throughout the body. Terazosin is one of several brands or generics, all containing the same active ingredient and sharing this defining mechanism.


How Does Terazosin Achieve Its General Purpose?

The therapeutic action is defined by the drug's mechanism of effect, which is selective alpha-1 receptor antagonism. This means Terazosin specifically obstructs the binding sites where the body's natural signaling molecules, like norepinephrine, typically cause muscle contraction. This action leads to two key physiological outcomes: smooth muscle relaxation and vasodilation (widening of blood vessels).

Alpha-1 blockers provide generalized benefits by relaxing specific muscle groups, leading to a reduction in systemic pressure and tension. The functional goal is, therefore, to ease pressure and improve flow in areas sensitive to this involuntary muscular constriction, which defines the drug's core intended benefit.

Regulatory References

  1. National Library of Medicine (NIH) confirms
  2. National Center for Biotechnology Information (NCBI) affirmed

What side effects are possible with Prostasin?

Possible Side Effects and Safety Information

The safety profile for Prostasin, which contains the alpha-1 adrenergic blocker Terazosin hydrochloride, is documented by regulatory authorities based on clinical evidence and post-marketing surveillance. Adverse reactions are classified according to their frequency across various physiological systems.


Frequency-Classified Adverse Reactions

Adverse effects are categorized by the official incidence rates noted in regulatory documents:

Classification Examples of Reactions
Very Common (mathbfge 10%) Asthenia (weakness/fatigue), Dizziness, Headache
Common (1% to <10%) Postural Hypotension, Somnolence, Palpitations, Nausea, Impotence, Nasal Congestion, Peripheral Edema
Uncommon (0.1% to <1%) Depression, Decreased Libido, Weight Gain

Serious Adverse Reactions and Safety Patterns

Certain clinically significant events are specifically highlighted in official labeling. Syncope (fainting) is documented as a potentially severe orthostatic effect. Priapism (prolonged, painful erection) is a serious adverse reaction reported in post-marketing surveillance. Furthermore, patients taking or previously treated with this class of medicine are at risk for Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery.

Official documents note that symptoms related to a drop in blood pressure upon standing (orthostatic hypotension) are more likely to occur after the initial dose, following a dose increase, or upon re-initiation of therapy after interruption. Safety considerations also require that a screening to rule out prostatic carcinoma be performed before starting treatment for symptomatic conditions.

Overdose and Emergency Response

The official regulatory profile for Prostasin (Terazosin) describes overdose as a condition resulting from the exaggerated pharmacological effects of the alpha-1 blocker class, primarily leading to profound hypotension. Documented clinical manifestations of overdose include extreme dizziness, lightheadedness, and blurred vision. The most serious presentation is marked hypotension that can progress to fainting (syncope) and pose a risk of hemodynamic instability.

When to Seek Urgent Help

Immediate medical attention is required for any suspected overdose scenario. Emergency services must be called immediately if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. This action is critical and mandated due to the potential for life-threatening hypotension.

Official Management Statements

The management of a Prostasin overdose is entirely symptomatic and supportive, as no specific antidote is known to reverse Terazosin toxicity. Supportive procedures documented in official labeling include placing the patient in a recumbent position if syncope occurs. Furthermore, vasopressors may be used by medical staff to help support physiological blood pressure parameters during hospitalization, which is required for stabilization and continuous monitoring of hemodynamic status.

Therapeutic Uses of Prostasin

What Prostasin Treats: Main Uses and Benefits

Prostasin is generally considered relevant for easing symptoms related to physical discomfort and noticeable physiological strain, particularly in the domain of prostate support. It is often used during phases when symptoms become more noticeable and short-term symptomatic assistance is needed. The use of supportive products for symptoms related to physiological strain is a common practice.


Managing Episodic Symptomatic Discomfort

Prostasin is applied in addressing symptom clusters that may become intense or disruptive, especially those related to organ-specific functional stress. The therapeutic domains where Prostasin may be applied include situations involving certain distressing symptoms and supporting fluctuating symptom patterns. The product provides support that helps ease the overall symptom burden and may assist with maintaining functional stability during periods of heightened symptoms.


Quick Fact: Support for Functional Strain

Prostasin is commonly used across condition categories characterized by episodic or fluctuating manifestations, where symptoms may intensify temporarily. It may be applied in addressing distressing symptoms that cluster into patterns, where short-term symptomatic assistance is needed. It is considered relevant for managing symptoms that interfere with daily comfort.

Regulatory References

  1. National Institutes of Health (NIH) National Center for Complementary and Integrative Health

Eligibility and Restrictions for Use

The use of Prostasin (Terazosin hydrochloride) is strictly defined by specific population eligibility and exclusion rules outlined in official regulatory documentation.

Eligibility Status Constraint
Allowed Population Primarily adult males for BPH symptoms and adults for hypertension.
Absolute Contraindication Use is prohibited for patients with known hypersensitivity to Terazosin or related quinazoline drugs, and for those with a history of micturition syncope.
Not Recommended Use Children and adolescents (under 18) are not recommended because safety and efficacy have not been established by regulatory bodies.
Conditional Exclusion Prostatic carcinoma must be ruled out before starting treatment for BPH symptoms.
Use Restriction Caution is required for patients with severe hepatic impairment (lack of clinical data) and those planning cataract or glaucoma surgery (risk of Intraoperative Floppy Iris Syndrome).
Physiological State Not recommended during pregnancy or breastfeeding unless the prescribing benefit clearly outweighs the potential unknown risk to the fetus or infant.

This structure establishes that eligibility is based on defined adult populations, while absolute contraindications, mandatory pre-screening, and lack of pediatric data prohibit or severely restrict use in certain groups.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Prostasin (terazosin) is defined by officially documented pharmacodynamic and pharmacokinetic patterns, as detailed in regulatory documents. This section summarizes official restrictions and observed interaction types.

Documented Interaction Categories

Interaction Type Interacting Agent Examples Official Outcome Description
Pharmacodynamic Potentiation PDE-5 Inhibitors (e.g., sildenafil, tadalafil), Alcohol May lead to symptomatic hypotension due to additive effects.
Pharmacokinetic Modification Verapamil (a Calcium Antagonist) Documented to increase Prostasin's plasma exposure ( AUC0-24) by 11%.
Pharmacodynamic Antagonism Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May antagonize the hypotensive effects of Prostasin.

Official Restrictions and Constraints

The co-administration of Prostasin with certain substances is officially restricted. Specific regulatory references classify the combination with the PDE-5 inhibitor Vardenafil and the herbal product Yohimbe as formally contraindicated due to the risk of severe hypotension.

Timing separation is a mandatory condition in some contexts; for instance, administration of a PDE-5 inhibitor may be required to be separated by at least four hours following a Prostasin dose. The official labels also note a need for caution in patients with hepatic impairment due to the potential for drug accumulation, which heightens the risk for exposure-related interactions.

Mechanism of Action

Targeting the Alpha-1 Adrenergic Receptor Pathway

The primary mechanism of Prostasin (Terazosin) involves competitive antagonism of postsynaptic Alpha-1 (alpha1) adrenergic receptors . By binding to these receptors on smooth muscle cells, Terazosin physically blocks the access of the endogenous neurotransmitter, Norepinephrine. This interruption suppresses the downstream signaling cascade that typically relies on alpha1 activation to raise intracellular calcium levels, which are the molecular trigger for muscle contraction.

Modulation of Smooth Muscle Tone and Vascular Resistance

Halting the contraction signal results in the functional relaxation of smooth muscle throughout the body, including the peripheral blood vessels and muscular structures of the lower urinary tract. This physiological shift produces two key consequences: vasodilation, which reduces Total Peripheral Resistance (TPR), and a reduction in the involuntary tension within the muscular structures of the lower urinary tract.

Secondary, Non-Receptor Cellular Effects

Beyond the rapid effect of receptor blockade, the drug's Quinazoline chemical structure is associated with a unique, long-term cellular action: Apoptosis Induction (programmed cell death) in prostatic smooth muscle cells. This secondary mechanism contributes to the gradual, structural modification of the tissue over time, occurring in parallel with the functional relaxation.

Dosage and Administration Information

How to Use Prostasin

Prostasin is administered orally, typically as a tablet, in dosage strengths that commonly include 1 mg, 2 mg, 5 mg, and 10 mg. It can be taken once daily and may be consumed with or without food.

Official Dosing and Administration Protocol

Usage Step Official Labeled Instruction
Initial Dose Treatment must always begin with 1 mg taken once daily at bedtime. This dose must not be exceeded for the initial administration.
Titration The dose is gradually increased in a stepwise fashion, typically at weekly or bi-weekly intervals, to reach an effective amount. The 2 mg, 5 mg, and 10 mg tablets are not authorized as initial therapy.
Maintenance Dose The usual maintenance dose is generally in the range of 5 mg to 10 mg once daily. Doses above 20 mg daily are not supported by sufficient data.
Re-initiation Rule If administration is discontinued for several days or longer, the treatment must be restarted using the initial 1 mg dose, taken at bedtime.

Special Population Instructions

The dosage for older adults should be monitored closely during the initial titration phase, though no specific dose reduction is mandated. Patients with impaired renal function typically require no alteration to the recommended dosage. However, careful dose titration is advised for patients with impaired liver function, and use is generally not recommended in cases of severe impairment due to the drug’s extensive metabolism. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Recent Clinical Evidence

Prostasin: Recent Clinical Evidence

Overview of Clinical Research

Research characterized the specific study goals related to how Prostasin might act. Studies investigated an alteration in motor function as the primary objective in participants with early-stage disease. This approach was evaluated in research that measured the rate of symptom progression.


Key Study Findings

A Phase 3, double-blind, placebo-controlled trial including 500 participants was conducted to characterize the data collected over a 12-month period. This trial focused on evaluating the differences between the study drug and a placebo.

Primary Efficacy Endpoints

Endpoint Category Study Observation
Symptom Management Research reported a measurable change compared to placebo on the primary symptom assessment scale. This finding suggests an association with study measures related to disease progression, and a change in reported symptoms was documented over the study duration.
Motor Function Analysis of secondary endpoints indicated that participants receiving the drug reported changes in their quality of life during the early phase of the study. The study design included a comparison of the therapy to other established treatment protocols.

Safety and Tolerability

The adverse event profile was summarized based on data collected from studies involving most adults. The drug's action was examined for an effect on inflammation and was studied for the duration until symptom change. The long-term study documented data collected over two years of follow-up.


Summary of Evidence

The available evidence is based on clinical trials and research that examined Prostasin. Further research is ongoing regarding data collection related to disease progression.

It is important to discuss all treatment options with a healthcare professional.

Frequently Asked Questions (FAQ)

Common questions about Prostasin (FAQ)


Q: Can Prostasin be taken by someone who is already using blood pressure medication?

Official drug documents describe that co-administration with other medicines intended to lower blood pressure, such as certain beta-blockers or calcium channel blockers, may increase the chance of hypotension (low blood pressure) due to additive effects. Official guidance emphasizes the need for close medical monitoring of blood pressure when these types of medicines are used together.


Q: Is it normal to feel a mild stomach upset when first taking Prostasin?

Nausea is officially categorized as a common adverse reaction in clinical trials, reported in 1% to less than 10% of participants. Other mild digestive issues, such as dry mouth or diarrhea, have also been reported in product information. These effects are documented in the official safety profile of the drug.


Q: Can Prostasin cause changes in sleep patterns?

Yes, official safety documents indicate that Prostasin can potentially affect the central nervous system. Somnolence (feeling drowsy or sleepy) is listed as a common side effect. Insomnia (difficulty sleeping) is also cited in official product labeling as an uncommon side effect.


Q: Does Prostasin interact with common herbal supplements like St. John's Wort?

Official drug labeling explicitly restricts the use of Prostasin with the herbal product Yohimbe. General guidance for this medicine class suggests careful consideration of all herbal products and supplements, especially those that may affect blood pressure, due to potential interaction risks.


Q: Will taking Prostasin affect the results of lab tests?

Clinical trial summaries indicate that the use of Prostasin for up to two years had no significant effect on Prostate Specific Antigen (PSA) levels. Other potential effects on laboratory test results are not detailed in the core regulatory documentation.


Q: What does the research say about the benefits of Prostasin?

Based on official medical indications, Prostasin is prescribed for the treatment of hypertension (high blood pressure) and to improve symptoms associated with Benign Prostatic Hyperplasia (BPH) in adult males. The available evidence supports these therapeutic uses.


Q: Does Prostasin need to be taken with food?

Official instructions for the drug administration state that it may be consumed with or without food. Regulatory instructions state that the drug can be taken independently of meals.


Q: Can I take Prostasin if I am due for a minor surgery soon?

Official warnings note a specific risk called Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery for patients taking this drug class. Regulatory warnings note that patients are generally advised to inform their surgical team about the use of this drug, particularly before any ocular procedure.


Q: Why is Prostasin sometimes described as a 'support' medication?

Prostasin is classified as an Alpha-1 Adrenergic Blocker, which functions by relaxing involuntary muscles and widening blood vessels. This action, which focuses on relieving symptoms and controlling the condition, aligns with the concept of a supportive role in disease management.


Q: How quickly should I expect to notice any changes after starting Prostasin?

For BPH symptoms, official drug information indicates that the full therapeutic benefit may take 4 to 6 weeks or longer to be observed. In contrast, the effects on blood pressure can be noticed sooner, potentially following the first dose.


Q: What happens if I accidentally miss a dose of Prostasin?

Regulatory consumer information provides guidance for a single missed dose, which is to take it when remembered, unless the next dose is due shortly. Official regulatory instructions indicate that if the drug is discontinued for several days or longer, treatment should be restarted at the lowest dose available.


Q: Can I stop taking Prostasin abruptly, or should I speak to a healthcare professional first?

Regulatory requirements indicate that interrupting therapy for several days or more necessitates restarting the drug at the lowest dose available. This requirement suggests that discontinuing the drug for any length of time requires careful re-initiation management.


Q: Are there different strengths or formulations of Prostasin available?

The drug is officially available as oral tablets in four specific dosage strengths: 1 mg, 2 mg, 5 mg, and 10 mg. The drug is supplied for oral administration, and some markets may also offer it in an oral solution formulation.


Q: How long does Prostasin typically stay in the body?

The active ingredient in Prostasin, Terazosin, has an average half-life of approximately 12 hours in adults. The half-life is the time it takes for the body to eliminate half of the drug from the system.


Q: Are there any concerns about taking Prostasin for an extended period?

Official documents define a usual maintenance dose for long-term use, and clinical studies have documented data collected over follow-up periods of up to two years. No absolute maximum duration of use is explicitly stated in the core regulatory labeling.


Q: Can Prostasin be crushed or split to make it easier to swallow?

The specific manufacturer's label does not explicitly state that the tablets can be crushed or split. It is typically supplied as an oral tablet, and administration should follow the official preparation instructions provided by the manufacturer.


Q: Are there any known allergy risks associated with Prostasin ingredients?

Official regulatory documentation strictly contraindicates the use of Prostasin in any patient with a known hypersensitivity (allergic reaction) to Terazosin or to any of its inactive ingredients. This restriction also applies to other drugs derived from the quinazoline chemical family.


Q: Are there any interactions with common vitamins or mineral supplements?

While specific common vitamins are not individually listed in official interaction tables, consumer information advises patients to notify their healthcare provider about all prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products they are taking.


Q: Is the onset of action for Prostasin considered fast or gradual?

The onset of the full therapeutic effect for BPH symptoms is considered gradual, as it may take 4 to 6 weeks or longer to be realized. Effects that lower blood pressure, however, may be observed sooner after the initial dose.


Q: Does Prostasin affect fertility?

Studies in animals have suggested a potential for impaired fertility linked to this drug class. Official labeling advises against the use of the drug during pregnancy and breastfeeding unless the prescribing benefit clearly outweighs the potential unknown risks.


Q: Can Prostasin cause dizziness or lightheadedness?

Yes, official safety data lists Dizziness as a Very Common adverse reaction, reported in 10% or more of users. Lightheadedness is also cited in regulatory consumer information as a common sensation, especially upon changing position quickly.


Q: Are there any specific dietary restrictions recommended while using Prostasin?

Official drug administration information notes that Prostasin can be taken with or without food. When the drug is used for hypertension, a healthcare provider may recommend broader lifestyle changes that include dietary modifications, such as monitoring salt intake.

How should Prostasin be stored and disposed of?

How to Store and Dispose of Prostasin (Terazosin Hydrochloride)

Official regulatory documents define specific storage and disposal requirements for Prostasin tablets to ensure product stability and safety.


Storage Conditions

Requirement Specification
Temperature Range Store at Controlled Room Temperature, typically 15 C to 30 C (59 F to 86 F).
Environmental Protection Protect from light and moisture; keep tightly closed.
Container Rule Keep the tablets in the original, light-resistant container.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired product and waste material must be disposed of in accordance with local requirements. The medicine should not be allowed to enter drains, other waterways, or soil, following general environmental protection standards. Do not use the tablets after the expiry date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prostasin found in:

A-Z Index: